BCAX (Bicara Therapeutics) Total Liabilities : $18.12 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bicara Therapeutics Total Liabilities?

Bicara Therapeutics's Total Liabilities for the quarter that ended in Dec. 2024 was $18.12 Mil.

Bicara Therapeutics's quarterly Total Liabilities declined from Jun. 2024 ($383.56 Mil) to Sep. 2024 ($14.62 Mil) but then increased from Sep. 2024 ($14.62 Mil) to Dec. 2024 ($18.12 Mil).

Bicara Therapeutics's annual Total Liabilities increased from Dec. 2022 ($105.51 Mil) to Dec. 2023 ($382.75 Mil) but then declined from Dec. 2023 ($382.75 Mil) to Dec. 2024 ($18.12 Mil).

Bicara Therapeutics Total Liabilities Historical Data

The historical data trend for Bicara Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicara Therapeutics Total Liabilities Chart

Bicara Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Total Liabilities

105.51

382.75

18.12

Bicara Therapeutics Quarterly Data
	Dec22	Sep23	Dec23	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial			-	382.75	383.56	14.62	18.12

Bicara Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Bicara Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	17.99	+	(0.131	+	2.2204460492503E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	18.12

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	509.996	-	491.875
	=	18.12

Bicara Therapeutics's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	17.99	+	(0.131	+	2.2204460492503E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	18.12

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	509.996	-	491.875
	=	18.12

Bicara Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Bicara Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Bicara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116

Website

https://www.bicara.com

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.